ERBB2 and neoplasm: As an optimal third- or later-line therapy, T-DXd was effective in T-DM1-resistant or T-DM1-refractory patients and achieved a tumour response rate of 61.4% and a median PFS of 19.4 months in the pivotal phase II HER2-positive metastatic breast cancer trial11.